Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesResponse to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677-1683.
Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, Fabbroni M, Fioravanti A, Frati E, Selvi E, Vitale A, Cantarini L, Frediani B, Galeazzi M. Gentileschi S, et al. Among authors: galeazzi m. Expert Opin Biol Ther. 2016 Oct;16(10):1311-2. doi: 10.1080/14712598.2016.1198765. Epub 2016 Jun 28. Expert Opin Biol Ther. 2016. PMID: 27266338 No abstract available.
Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.
Cantarini L, Fabbroni M, Talarico R, Costa L, Caso F, Cuneo GL, Frediani B, Faralli G, Vitale A, Brizi MG, Sabadini L, Galeazzi M. Cantarini L, et al. Among authors: galeazzi m. Medicine (Baltimore). 2015 Jul;94(30):e1170. doi: 10.1097/MD.0000000000001170. Medicine (Baltimore). 2015. PMID: 26222847 Free PMC article.
Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: galeazzi m. Clin Rheumatol. 2017 Jan;36(1):191-197. doi: 10.1007/s10067-016-3506-4. Epub 2016 Dec 16. Clin Rheumatol. 2017. PMID: 27981463
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
Gentileschi S, Rigante D, Vitale A, Sota J, Frediani B, Galeazzi M, Cantarini L. Gentileschi S, et al. Among authors: galeazzi m. Clin Rheumatol. 2017 Jul;36(7):1687-1690. doi: 10.1007/s10067-017-3688-4. Epub 2017 May 23. Clin Rheumatol. 2017. PMID: 28536823 Review.
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Gentileschi S, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L. Fabiani C, et al. Among authors: galeazzi m. Clin Rheumatol. 2019 Feb;38(2):407-415. doi: 10.1007/s10067-018-4228-6. Epub 2018 Aug 11. Clin Rheumatol. 2019. PMID: 30099655
506 results